The paper cited documents published by China’s National Intellectual Property Administration saying that the patent was issued on August 11
Current Affairs : China’s antibody master CanSino Biologics Inc has won a patent endorsement from Beijing for its Covid-19 immunization applicant Ad5-nCOV, state media detailed, refering to archives from the nation’s protected innovation controller.
It is the first Covid-19 antibody patent conceded by China, state-claimed paper People’s Daily provided details regarding Sunday.
The paper refered to archives distributed by China’s National Intellectual Property Administration saying that the patent was given on Aug. 11.
Saudi Arabia said for the current month it intends to start Phase III clinical preliminaries for the CanSino antibody. CanSino has said it is additionally in chats with Russia, Brazil and Chile to dispatch Phase III preliminaries in those nations.
CanSino’s Hong Kong shares rose around 14% in Monday’s morning meeting. Its Shanghai shares rose by 6.6% as of early afternoon.
Aditi Mehta 